Phase 3 N=676 Randomized Quadruple-blind Prevention

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Human Papillomavirus (HPV) Infection

Bottom Line

View on ClinicalTrials.gov: NCT00481767 ↗

Enrolled (actual)

676

Serious AEs

4.6%

Results posted

Mar 2011

Primary outcome: Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Cervarix (Biological); Placebo Al(OH)3 (Drug)
Age: Pediatric, Adult · 10+ yrs
Sex: Female
Sponsor: GlaxoSmithKline
Primary completion: Feb 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies	130; 4; 190; 5; 128; 2	—
PRIMARY Geometric Mean Titers (GMTs) of Anti-HPV-16 and Anti-HPV-18 Antibodies	18591.3; 4.8; 10664.0; 5.3; 6409.8; 3.9	—
SECONDARY Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies	130; 1; 190; 3; 128; 2	—
SECONDARY GMTs for Anti-HPV-16 and Anti-HPV-18 Antibodies	5340.2; 4.5; 3732.6; 4.9; 4016.2; 4.7	—
SECONDARY Number of Subjects With Any and Grade 3 Solicited Local Symptoms	309; 116; 2; 0; 15; 7	—
SECONDARY Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	19; 10; 0; 0; 7; 2	—
SECONDARY Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	235; 142; 5; 1; 3; 4	—
SECONDARY Number of Subjects With NOCDs and Other MSCs	10; 8; 1; 3; 289; 161	—
SECONDARY Number of Subjects With Serious Adverse Events (SAEs)	12; 10; 17; 14	—
SECONDARY Number of Subjects With Pregnancies and Their Outcomes	1; 0; 3; 3; 5; 5	—
SECONDARY Number of Senegalese Subjects With Clinically Relevant Abnormalities in Parameters Assessed	8; 4; 0; 0; 0; 0	—
SECONDARY Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Parameters Assessed	2; 2; 0; 1; 1; 1	—
SECONDARY Number of Senegalese Subjects With Clinically Relevant Abnormalities in Parameters Assessed	8; 4; 0; 0; 0; 0	—
SECONDARY Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Parameters Assessed	2; 2; 0; 1; 1; 1	—

Summary

Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries. The incidence of cervical cancer varies depending on the region of the world. Africa has some of the highest age-standardized incidence and mortality rates in the world (Eastern Africa 42.7 and 34.6 per 100 000; Southern Africa 38.2 and 22.6 per 100 000; Western Africa 29.3 and 23.8 per 100 000; Middle Africa 28.0 and 23.0 per 100 000). As in the majority of developing countries, organization of cervical cancer screening programs in Africa is difficult to manage, especially in rural areas. HPV prophylactic vaccination could therefore clearly and efficiently decrease the incidence of cervical cancer. The current study is designed to assess the immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 AS04 vaccine in female subjects enrolled from multiple countries in Africa. Ideally, HPV vaccination should be performed before onset of sexual activity, since studies have shown that acquisition of high-risk HPV occurs soon after sexual debut. This study will therefore be performed in subjects aged 10 to 25 years of age.

Eligibility Criteria

Inclusion Criteria

Subjects who the investigator believes that they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol should be enrolled in the study.
A female between, and including, 10 and 25 years of age at the time of the first vaccination.
Written or oral, signed or thumb printed or witnessed informed consent obtained from the subject prior to enrolment. For subjects below legal age of consent, written or oral, signed or thumb printed or witnessed informed consent obtained from the subject's parent or legally acceptable representative. In addition, a written or oral, signed or thumb printed and witnessed informed assent must be obtained from the subject.
Free of obvious health problems as established by medical history, clinical examination and laboratory testing before entering into the study.
Subjects must have a negative urine pregnancy test at the screening visit and at Visit 1 (Day 0).
Subjects must be seronegative for human immunodeficiency virus (HIV) at the screening visit.
Subjects must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. Subjects who reach menarche during the study and therefore are of childbearing potential must agree to follow the same precautions.
Subjects must have had no more than 6 sexual partners prior to enrolment.
Subjects must be willing to undergo HIV voluntary counselling and testing and must be willing to be informed of their HIV status. Subjects below legal age of consent must also be willing to have their parent or legally acceptable representative informed of their HIV status.

Exclusion Criteria

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 12).
Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned administration during the study period.
Administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. Enrolment will be deferred until the subject is outside of specified window.
Planned administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after any dose of study vaccine.
Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
Previous administration of components of the investigational vaccine.
Cancer or autoimmune disease under treatment.
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection based on laboratory testing performed during the screening visit.
Hypersensitivity to latex.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control.
Acute disease at the time of enrolment.
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory testing performed at the screening visit.
History of any neurologic disorders or seizures.
Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
Pregnant or breastfeeding female.
A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose.
Concurrently participating in another clinical study, at any time during the stud

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00481767). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.